IGLV3-21^R110 status and prognostic value in an integrative cohort of 1487 patients with CLL (n = 1323) or MBL (n = 164). (A) Oncoprint representation showing the disease stage, IGHV gene SHM status, epigenetic subtypes, and stereotyped subset of IGLV3-21^R110 positive and negative CLL (left) and MBL (right). Bar plots on the right show the frequency of each variable in IGLV3-21^R110 positive and negative CLL/MBL. (B) TTFT curves of patients with CLL stratified based on epigenetic subtype. Patients classified as having i-CLL were divided based on the presence or absence of IGLV3-21^R110. i-CLL without IGLV3-21^R110 was further stratified based on their IGHV gene SHM status as M-CLL or U-CLL. (C) Multivariate analysis of TTFT integrating disease stage (Binet stage), epigenetic subtypes, and IGLV3-21^R110 in patients with CLL. (D) TTFT curves of patients with CLL stratified by IGHV gene SHM status and presence/absence of IGLV3-21^R110. (E) TTFT curves of patients with CLL stratified by IGHV gene SHM status, presence/absence of IGLV3-21^R110, and stereotyped subset. Patients were first stratified based on IGLV3-21^R110. CLL without IGLV3-21^R110 was divided based on their IGHV gene SHM status. CLL carrying IGLV3-21^R110 were stratified based on their stereotyped subset as stereotyped subset #2 (#2), no stereotyped subset #2 (no #2), or unknown subset (unknown). (F) Multivariate analysis of TTFT integrating disease stage (Binet stage), IGHV gene SHM status, stereotyped subset #2, and IGLV3-21^R110 in patients with CLL. (G) Multivariate analysis of TTFT integrating Binet stage, IGHV gene SHM status, stereotyped subset #2, IGLV3-21^R110, TP53 mutation/deletion, trisomy 12, and deletions of 11q and 13q in patients with CLL.